company background image
E08A

Exagen DB:E08A Stock Report

Last Price

€2.60

Market Cap

€42.5m

7D

-1.5%

1Y

-65.1%

Updated

02 Feb, 2023

Data

Company Financials +

E08A Stock Overview

Exagen Inc. develops and commercializes various testing products based on its cell-bound complement activation products technology under the AVISE brand in the United States.

E08A fundamental analysis
Snowflake Score
Valuation4/6
Future Growth1/6
Past Performance0/6
Financial Health5/6
Dividends0/6

My Notes

New

Notes are coming soon

Exagen Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Exagen
Historical stock prices
Current Share PriceUS$2.60
52 Week HighUS$8.40
52 Week LowUS$2.02
Beta1.2
1 Month Change13.04%
3 Month Change6.56%
1 Year Change-65.10%
3 Year Change-86.10%
5 Year Changen/a
Change since IPO-83.32%

Recent News & Updates

Recent updates

Shareholder Returns

E08ADE BiotechsDE Market
7D-1.5%-2.6%1.2%
1Y-65.1%4.5%-11.7%

Return vs Industry: E08A underperformed the German Biotechs industry which returned 4.5% over the past year.

Return vs Market: E08A underperformed the German Market which returned -11.7% over the past year.

Price Volatility

Is E08A's price volatile compared to industry and market?
E08A volatility
E08A Average Weekly Movement25.0%
Biotechs Industry Average Movement5.6%
Market Average Movement5.1%
10% most volatile stocks in DE Market10.6%
10% least volatile stocks in DE Market2.4%

Stable Share Price: E08A is more volatile than 90% of German stocks over the past 3 months, typically moving +/- 25% a week.

Volatility Over Time: E08A's weekly volatility has increased from 16% to 25% over the past year.

About the Company

FoundedEmployeesCEOWebsite
2002221John Aballihttps://www.exagen.com

Exagen Inc. develops and commercializes various testing products based on its cell-bound complement activation products technology under the AVISE brand in the United States. It enables rheumatologists to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms.

Exagen Inc. Fundamentals Summary

How do Exagen's earnings and revenue compare to its market cap?
E08A fundamental statistics
Market Cap€42.48m
Earnings (TTM)-€36.74m
Revenue (TTM)€41.62m

1.0x

P/S Ratio

-1.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
E08A income statement (TTM)
RevenueUS$45.42m
Cost of RevenueUS$22.84m
Gross ProfitUS$22.57m
Other ExpensesUS$62.66m
Earnings-US$40.09m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-2.46
Gross Margin49.70%
Net Profit Margin-88.27%
Debt/Equity Ratio49.8%

How did E08A perform over the long term?

See historical performance and comparison